Board Certification

Society of Infectious Disease Pharmacists (SIDP)

Antimicrobial Stewardship Certification

Northeast Ohio Medical University (NEOMED)

Teaching Certificate

American College of Clinical Pharmacy (ACCP) Academy

Teaching and Learning Certificate

Immunization Certificate

Basic Life Support (BLS) Instructor Certification

Medication Therapy Management Certification

Advanced Cardiac Life Support (ACLS) Instructor Certification

Phi Lambda Sigma, National Pharmacy Leadership Society

American College of Clinical Pharmacy

American Association of Colleges of Pharmacy

Society of Infectious Diseases Pharmacists

Infectious Diseases Society of America

Cedarville University, located in southwest Ohio, is an accredited, Christ-centered, Baptist institution with an enrollment of 4,550 undergraduate, graduate, and online students in more than 150 areas of study. Founded in 1887, Cedarville is recognized nationally for its authentic Christian community, rigorous academic programs, strong graduation, and retention rates, accredited professional and health science offerings, and high student engagement ranking. For more information about the University, visit www.cedarville.edu.

Cedarville University

Dr. Jenkins obtained his doctorate of Pharmacy from Northeast Ohio Medical University (NEOMED) in 2012. Following graduation, Jenkins completed a postgraduate pharmacy practice residency with Summa Health System, where he focused his training in adult
internal medicine and infectious disease. Dr. Jenkins maintains a clinical practice in infectious disease and serves as the co-director of antimicrobial stewardship at Atrium Medical Center, where he helps to lead antimicrobial stewardship initiatives for the Premier Health Partners system. 

During the COVID-19 pandemic, Dr. Jenkins has been heavily involved with treating patients and developing therapeutic protocols for hospitals in his network, and he has also aided with strategic response efforts for Cedarville University and several surrounding communities. 

Dr. Jenkins is an active member of the pharmacy profession, and he currently serves within the leadership of several professional organizations. His research interests include subjects related to infectious disease, antimicrobial stewardship, interprofessional education, and student professional development. He has provided dozens of professional presentations at the regional and national levels, fielded over 200 interviews with local, national, and international media outlets.

Vaccines

Superbugs

Viruses

COVID-19

Infectious Diseases

Coronavirus

Antibiotics

Bacteria

Antibiotic Resistance

Outbreak Experience

Coronavirus deaths surpass 5,000 in Ohio Monday

Doctors explain 'antibody cocktail' given to Trump; Ohio lawmakers tested for COVID-19

Doctors weigh in on pause of COVID-19 vaccine trial, future of vaccine

Doctor stresses risk mitigation as students return to school amid COVID-19 spread

Uncertainty over fate of New York State Fair makes planning difficult for vendors

'We won't be completely out of the woods': Ohio preparing to reopen gradually

Sub-award from Centers for Diseases Control and Prevention Grant

Midwest integration of the National HIV curriculum

covering-remdesivir-contact-an-expert-from-cedarville-first

Associate Professor of Pharmacy Practice & Clinical Specialist, Infectious Diseases

 There has been a lot of talk about treatment, vaccinations and drugs that are being used during the CVOID-19 pandemic.

The latest is Remdesivir – and it is getting a lot of attention.
 The US's Food and Drug Administration (FDA) has authorised emergency use of the Ebola drug remdesivir for treating the coronavirus. The authorisation means the anti-viral drug can now be used on people who are hospitalised with severe Covid-19. A recent clinical trial showed the drug helped shorten the recovery time for people who were seriously ill. However, it did not significantly improve survival rates. Experts have warned the drug - which was originally developed to treat Ebola, and is produced by Gilead pharmaceutical company in California - should not be seen as a "magic bullet" for coronavirus. What do we know about remdesivir?  The drug did not cure Ebola, and Gilead says on its website: "Remdesivir is an experimental medicine that does not have established safety or efficacy for the treatment of any condition." Gilead also warns of possible serious side-effects. However, President Trump has been a vocal supporter of remdesivir as a potential treatment for the coronavirus. In its clinical trial, whose full results are yet to be released, the US National Institute of Allergy and Infectious Diseases (NIAID) found that remdesivir cut the duration of symptoms from 15 days down to 11.   The trials involved 1,063 people at hospitals around the world - including the US, France, Italy, the UK, China and South Korea. Some patients were given the drug and others were given a placebo (dummy) treatment. Dr Anthony Fauci who runs NIAID, said that remdesivir had "a clear-cut, significant, positive effect in diminishing the time to recovery". However, although remdesivir may aid recovery - and possibly stop people having to be treated in intensive care - the trials did not give any clear indication whether it can prevent deaths from coronavirus.  May 02 - BBC

 There are still a lot of questions to be asked:

When could it be ready for mass distribution? How is it administered? Who can get it? And how much will it cost?  If you are a journalist covering this emerging issue – then let our experts help. Dr. Zach Jenkins is an infectious disease expert at Cedarville University. He is available to speak with media about this topic – simply click on his icon to arrange an interview. 

Covering Remdesivir – Contact an expert from Cedarville first


bare-shelves-and-closed-facilities-is-america-facing-a-food-shortage

Earlier this week, South Dakota based, Smithfield Foods was ordered to closed its Sioux Falls pork production facility because workers at the plant tested positive for COVID-19. It may be one facility; however, it is responsible for five percent of all the packaged pork in America. While the plant is making the decision to close indefinitely, President and CEO Kenneth Sullivan said in the news release that the closure "is pushing our country perilously close to the edge in terms of our meat supply." The Sioux Falls, South Dakota, plant accounts for 4% to 5% of the nation's pork production, the company says. "We have continued to run our facilities for one reason: to sustain our nation’s food supply during this pandemic," Sullivan said. "We believe it is our obligation to help feed the country, now more than ever. We have a stark choice as a nation: We are either going to produce food or not, even in the face of COVID-19." The release said the plant will be shut down until "further direction is received from local, state and federal officials." Employees will be compensated for the next two weeks, but there was no mention of payment if the plant is closed for longer. April 13 – USA Today  And it is not just Smithfield facing trouble. Tyson Foods and National Beef Packing are also shutting doors at facilities in Iowa. So, what will this mean for American supermarkets, consumers and a nation already worried about supply? Is there any way to keep production sustainable amidst a COVID-190 outbreak?   If you are a journalist covering this emerging issue – then let our experts help. Dr. Zach Jenkins is an infectious disease expert at Cedarville University. He is available to speak with media about this topic – simply click on his icon to arrange an interview.


Bare shelves and closed facilities – is America facing a food shortage?

the-consequences-of-ending-early-is-a-second-wave-of-covid19-inevitable

 America is in lockdown. As the COVID-19 virus spreads to just about every corner of America and the planet for that matter, extreme measures are being brought in by various levels of local, state and the federal government to help contain the spread of this virus that is growing in near exponential numbers daily.

Despite the White House advising all Americans to practice social distancing, the number of coronavirus cases in the US continues to rise. So, governors across the nation are taking stronger action by issuing stay-at-home orders in their states. By March 30, at least 27 states will have those orders in effect. Those states contain more than 225 million people -- more than two-thirds of the country's population. CNN - March 28  And as Americans comply with these orders, there’s a growing anticipation about when people will be able to return to work and resume a semi-normal routine. Some are saying weeks, others indicating months. But the reality is, as much as many yearn for normalcy, going back too early could come with even steeper consequences than waiting the epidemic out. If there is a second wave of COVID-19 infections – it could be disastrous. What would a second wave look like and how would it spread? Can people be re-infected? Does America have the front-line capacity to take on another fresh round of infections? Can the country’s stretched medical system handle more patients? And how much longer would it take to try and contain the spread of COVID-19 for a second time?   There are a lot of questions to be answered, and that’s where our experts can help. Dr. Zach Jenkins is an infectious disease expert at Cedarville University. He is available to speak with media about this topic – simply click on his icon to arrange an interview. 




The consequences of ending early - Is a second wave of COVID-19 inevitable?

Dr. Zach Jenkins provides an update on the coronavirus on CBN TV

Cedarville University Infectious Disease Expert on COVID-19

Coronvirus Update from Dr  Zach Jenkins

A year into the coronavirus pandemic, there are signs of hope - like several vaccines rolled out around the world - and still more challenges - like at least three variant strains that have emerged so far. As the virus and the world's response becomes more complicated, more questions arise. Are these variants more infectious? Are they more dangerous? Will existing vaccines be as effective against them? Dr. Zachary Jenkins, Associate Professor of Pharmacy Practice at Cedarville University, speaks to NewsPoint360 about how viruses mutate, how to modify the vaccines to tackle these new strains, and the need for continued precautions even after the majority of the public is vaccinated.

Learn more about Zachary Jenkins's expertise and media appearances here:  https://expertfile.com/experts/zachary.jenkins

NewsPoint360 is a news organization focused on giving credible experts a platform through video interviews that are uniquely designed for media and other key audiences looking for knowledgeable perspectives on trending stories.

Visit other NewsPoint360 channels:
Website: https://newspoint360.net/
Twitter: http://np360media.net/Twitter
LinkedIn: http://np360media.net/LinkedIn
YouTube: http://np360media.net/YouTube

Dr. Zachary Jenkins on Immunization and the Variant Strains of COVID-19

The WHIO TV I-Team investigated just how long a booster shot will further protect people from COVID 19? Dr. Zach Jenkins from Cedarville University comments on this intriguing question.

COVID Vaccine

How Long will Booster Shot Protect from COVID?

Dr. Zach Jenkins discusses new CDC guidelines on The National Desk.

The National Desk

Some medical experts are predicting there will be a global measles outbreak due to 22 million children missing their measles vaccine in 2021. What is the possibility for such an outbreak? Dr. Zach Jenkins, infectious disease expert from Cedarville University, comments on this developing story on The National Desk with Jan Jeffcoat.

Select Inquiry Type